Effective ILM & ERM staining


Effective ILM & ERM staining, high purification – minimum 97% purity


MembraneBlue-Dual® is a dye to stain both the ILM as well as the ERM and PVR membrane, without compromising the staining effect within one injection.

By injecting MembraneBlue-Dual® in the vitreous cavity the membrane will be clearly stained and easily distinguished 
from the underlying, unstained retina and can be removed selectively.

MembraneBlue-Dual® is a stable mix and stains the ILM at the same level as ILM-Blue® and stains the ERM and PVR at a higher level than the classic MembraneBlue.

Due to an integrated carrier 4% PEG solution, MembraneBlue-Dual® can be injected in a BSS filled eye and sinks immediately as a cohesive ball to the fundus of  the eye and only stains the targeted tissue without diffusion throughout the whole globe.


Effective ILM & ERM staining due to high purification – minimum 97% purity
MEMBRANEBLUE-DUAL®: Dye for staining ILM, ERM & PVR membranes consists of: 

Combination of TrypanBlue 0,15% + BBG 0,025% + 4% PEG

Highly purified TB + BBG – minimum 97% purity


Advanced injection characteristics due “carrier” 4% PEG solution
Creates better injection characteristics under BSS.
Sinks immediately to posterior pole as a cohesive ball. 
Stains only target tissue and no diffusion throughout the eye.


Specifications MEMBRANEBLUE-DUAL® 
Composition of one 0.5ml syringe

Brilliant Blue G: 0.125 mg

Trypan Blue: 0.75 mg

PEG: 4% PEG 3350

Concentration: 1.75 g/l

pH-value: 7.3 – 7.6

Osmolality: 301-369 mOsm/kg H2O

Play Video


Purity & safety

MembraneBlue-Dual®is produced according to Current Good Manufacturing Practice (CGMP). MembraneBlue-Dual® is produced with highly purified BBG + Trypanblue at a drug substance level.

Safety tests

Toxicity tests on ARPE-19 human retinal pigment epithelium cells showed an advantageous safety profile of the new products MembraneBlue-Dual®. Increased purity of the dyes as well as the addition of PEG3350 results in even safer products. Safety testing was complemented by electron microscopy ultrastructural analysis and in vitro cytotoxicity tests according to ISO-10993.

Patent protected

USA (6,696,430B1, 6,372,449, 20080090914A1), Australia (75731 8), Japan (4200222), Europe (EP 1 819 366, B1). Technology licensed from D.Western Therapeutics Institute, Inc., Japan.

Do you have a question?

Scroll to Top